Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy

Uretsky, 1983, The acute hemodynamic effects of a new agent, MDL 17;043, in the treatment of congestive heart failure, Circulation, 67, 823, 10.1161/01.CIR.67.4.823 Baim, 1983, Evaluation of a new bipyridine inotropic agent—milrinone—in patients with congestive heart failure, N Engl J Med, 309, 748, 10.1056/NEJM198309293091302 Petein, 1984, Hemodynamic effects of a new inotropic agent, piroximone (MDL 19,205), in patients with chronic heart failure, JACC, 4, 364, 10.1016/S0735-1097(84)80227-2 Mancini, 1984, Hemodynamic and clinical benefits of CI-914, a new cardiotonic agent, Circulation, 70, II 1981 Dage, 1982, Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1, 3 Dihydro-4 Methyl- 5[4-(Methylthio) — Benzoyl]-ZH-Imidazol-2-One), J Cardiovasc Pharmacol, 4, 500, 10.1097/00005344-198205000-00023 Kariya, 1982, Biochemical studies on the mechanism of cardiotonic activity of MDL-17,043. Possible involvement of cyclic AMP phosphodiesterase inhibition, J Cardiovasc Pharmacol, 4, 509, 10.1097/00005344-198205000-00024 Amin, 1984, Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic, severe heart failure, Am Heart J, 108, 1285, 10.1016/0002-8703(84)90755-5 Martin, 1984, Myocardial energetics and clinical response to the cardiotonic agent MDL 17,043 in advanced heart failure, JACC, 4, 875, 10.1016/S0735-1097(84)80046-7 Kereiakes, 1984, Intravenous and oral MDL 17,043 (a new inotropvasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients, JACC, 4, 884, 10.1016/S0735-1097(84)80047-9 Amin, 1985, Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure, Am Heart J, 109, 91, 10.1016/0002-8703(85)90421-1 Viquerat, 1985, Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17,043, a new inotropic vasodilator agent, in patients with severe heart failure, JACC, 5, 326, 10.1016/S0735-1097(85)80054-1 Shah, 1985, Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL 17,043): poor long-term results despite early hemodynamic and clinical improvement, Circulation, 71, 326, 10.1161/01.CIR.71.2.326 Uretsky, 1985, MDL 17,043 therapy in severe congestive heart failure; characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response, JACC, 5, 1414, 10.1016/S0735-1097(85)80358-2 Rubin, 1985, MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure, JACC, 5, 1422, 10.1016/S0735-1097(85)80359-4 Amin, 1985, Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure, Am Heart J, 109, 1006, 10.1016/0002-8703(85)90242-X Strain, 1985, Effects of a new cardiotonic agent, MDL-17,043, on myocardial contractility and left ventricular performance in congestive heart failure, Am Heart J, 110, 91, 10.1016/0002-8703(85)90520-4 Weber, 1980, Long-term vasodilator therapy with trimazosin in chronic cardiac failure, N Engl J Med, 303, 242, 10.1056/NEJM198007313030502 Weber, 1982, Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure, Circulation, 65, 1213, 10.1161/01.CIR.65.6.1213 Smith, 1985, Epidemiology of congestive heart failure, Am J Cardiol, 55, 3A, 10.1016/0002-9149(85)90789-1 Frommer, 1982, 1 Califf, 1982, The prognosis in the presence of coronary artery disease, 31 Cohn, 1982, Clinical definitions and studies, 1 Wilson, 1983, Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity, JACC, 2, 403, 10.1016/S0735-1097(83)80265-4 Massie, 1981, Long term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements, Circulation, 63, 269, 10.1161/01.CIR.63.2.269 Maskin, 1984, High prevalence of nonsustained ventricular tachycardia in severe congestive heart failure, Am Heart J, 107, 896, 10.1016/0002-8703(84)90824-X Weber, 1981, Contractile mechanics and interaction of the right and left ventricles, Am J Cardiol, 47, 685, 10.1016/0002-9149(81)90556-7 Bennotti, 1980, Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease, Circulation, 62, 28, 10.1161/01.CIR.62.1.28 Monrad, 1985, Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure, Circulation, 71, 972, 10.1161/01.CIR.71.5.972 Weber, 1981, Amrinone and exercise performance in patients with chronic cardiac failure, Am J Cardiol, 48, 164, 10.1016/0002-9149(81)90586-5 Weber, 1982, Cardiotonic agents in the management of chronic cardiac failure, Am Heart J, 103, 639, 10.1016/0002-8703(82)90469-0 Likoff, 1984, Amrinone in the treatment of chronic cardiac failure, JACC, 3, 1282, 10.1016/S0735-1097(84)80189-8 Weber, 1982, Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure, Circulation, 66, 1262, 10.1161/01.CIR.66.6.1262 Franciosa, 1982, Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo, Am Heart J, 104, 587, 10.1016/0002-8703(82)90231-9